Endo International PLC
LSE:0Y5F
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0003
692.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Endo International PLC
Income from Continuing Operations
Endo International PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Endo International PLC
LSE:0Y5F
|
Income from Continuing Operations
-$2.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Income from Continuing Operations
-$146.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Income from Continuing Operations
$465.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
31%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Income from Continuing Operations
-$72.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-3%
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Income from Continuing Operations
€75.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Income from Continuing Operations
-€4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
7%
|
|
Endo International PLC
Glance View
Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.
See Also
What is Endo International PLC's Income from Continuing Operations?
Income from Continuing Operations
-2.9B
USD
Based on the financial report for Dec 31, 2022, Endo International PLC's Income from Continuing Operations amounts to -2.9B USD.
What is Endo International PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
-411%
Over the last year, the Income from Continuing Operations growth was -411%.
You don't have any saved screeners yet
